NuCana plc Publishes New Data from NuTide:303 Study
Ticker: NCNA · Form: 6-K · Filed: Oct 14, 2025 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-data, biotech, press-release
TL;DR
NuCana plc dropped new clinical data for their cancer drug tech on Oct 14.
AI Summary
On October 14, 2025, NuCana plc announced the publication of new data from its NuTide:303 clinical study. The study focuses on the company's ProTide technology, which aims to improve the delivery of nucleoside analogues for cancer treatment.
Why It Matters
This data release is important for NuCana plc as it provides updated clinical evidence for their ProTide technology, potentially impacting future development and investor confidence in their cancer therapies.
Risk Assessment
Risk Level: medium — The filing is a routine update on clinical study data, which carries inherent risks related to trial outcomes and regulatory approval, but does not indicate immediate financial distress or major operational changes.
Key Players & Entities
- NuCana plc (company) — Registrant
- NuTide:303 (study) — Clinical study
- October 14, 2025 (date) — Date of press release
FAQ
What is the primary focus of the NuTide:303 clinical study?
The NuTide:303 clinical study focuses on the publication of new data related to NuCana plc's ProTide technology.
When did NuCana plc issue the press release regarding the new data?
NuCana plc issued the press release on October 14, 2025.
What is the Commission File Number for NuCana plc's 6-K filing?
The Commission File Number is 001-38215.
What is NuCana plc's principal executive office address?
NuCana plc's principal executive office is located at 3 Lochside Way, Edinburgh EH12 9DT, United Kingdom.
Does NuCana plc file annual reports under Form 20-F or Form 40-F?
NuCana plc files annual reports under Form 20-F.
Filing Stats: 350 words · 1 min read · ~1 pages · Grade level 15.3 · Accepted 2025-10-14 08:15:58
Filing Documents
- d88344d6k.htm (6-K) — 10KB
- d88344dex991.htm (EX-99.1) — 15KB
- 0001193125-25-238219.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Ian Webster Name: Ian Webster Title: Interim Chief Financial Officer (Principal Financial and Accounting Officer) Date: October 14, 2025